![Matthew Wood](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de Matthew Wood
Entité | Type d'entité | Industrie | |
---|---|---|---|
Evox Therapeutics Ltd.
![]() Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.
11
| Holding Company | Biotechnology | 11 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Matthew Wood via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
ABLYNX | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Actio Biosciences, Inc.
![]() Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Pharmaceuticals: Major | Founder | |
Imperial College London | College/University | Graduate Degree | |
University of Aberdeen | College/University | Undergraduate Degree | |
REDX PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
Leweston School | Director/Board Member | ||
Hy. Duke & Son Ltd.
![]() Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Specialty Stores | Corporate Officer/Principal | |
OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Equipment/Instruments | Director/Board Member | |
Velia, Inc.
![]() Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Packaged Software | Chief Executive Officer | |
Tune Therapeutics, Inc.
![]() Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Pharmaceuticals: Major | Director/Board Member | |
Larkham Ltd. | Director/Board Member | ||
METACRINE, INC. | Biotechnology | Director/Board Member | |
ASSEMBLY BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Scripps Clinic & Research Foundation | Corporate Officer/Principal | ||
Oxford BioTherapeutics Ltd.
![]() Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
University of Southern California
![]() University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | College/University | Corporate Officer/Principal | |
Duke University Medical Center | College/University | Corporate Officer/Principal | |
The Royal Australasian College of Physicians | Corporate Officer/Principal | ||
Duke Clinical Research Institute
![]() Duke Clinical Research Institute Pharmaceuticals: OtherHealth Technology Duke Clinical Research Institute manufactures medical and botanical products. It offers specialized patient databases and clinical and operational expertise. The firm accelerates the development of therapies, diagnostics, and medical devices to humans. The company was founded in 1969 and is headquartered in Durham, NC. | Pharmaceuticals: Other | Corporate Officer/Principal | |
University of Melbourne
![]() University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | College/University | Doctorate Degree | |
Lone Pine Capital (UK) Ltd.
![]() Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Investment Managers | Chief Executive Officer | |
The Bridport Literary Festival Ltd. | Director/Board Member | ||
Sgw Research Ltd. | Director/Board Member | ||
Theolytics Ltd.
![]() Theolytics Ltd. BiotechnologyHealth Technology Theolytics Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
University of Salford | College/University | Undergraduate Degree | |
ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Director/Board Member | |
Freeline Therapeutics Ltd.
![]() Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
The University of Western Australia | College/University | Undergraduate Degree | |
University of Oxford | College/University | Undergraduate Degree | |
BARINTHUS BIOTHERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Biotechnology | Director/Board Member | |
MiroBio Ltd.
![]() MiroBio Ltd. BiotechnologyHealth Technology Mirobio Ltd. operates as a biologics company focusing on autoimmune and inflammatory disorders. The firm develops antibody modulators of immune cell receptors, an approach that has potential across a range of diseases, with an initial focus on auto-immune disease. The company was founded by Richard Cornall and Simon Davis on October 8, 2018 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
Tin Alley Ventures
![]() Tin Alley Ventures Investment ManagersFinance Tanarra Ventures Pty Ltd (Tanarra Ventures) is a venture capital firm subsidiary of Tanarra Group Pty Ltd founded in 2005 by John Wylie. The firm is headquartered in Melbourne, Australia. | Investment Managers | Private Equity Investor | |
Chimeron Bio Corp.
![]() Chimeron Bio Corp. Medical SpecialtiesHealth Technology Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck. | Medical Specialties | Director/Board Member | |
Pepgen Ltd.
![]() Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Packaged Software | Director/Board Member | |
Macrophox Ltd.
![]() Macrophox Ltd. BiotechnologyHealth Technology Macrophox Ltd. engages in the provision of research and experimental development on biotechnology. The company was founded on March 12, 2018 and is headquartered in Woodstock, The United Kingdom. | Biotechnology | Director/Board Member | |
Royal Institute of Technology | College/University | Graduate Degree | |
JDRF International
![]() JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member | |
Thomson Reuters Holdings AB | Corporate Officer/Principal | ||
IsletOne Therapeutics | Founder | ||
Stockholm Business School | College/University | Masters Business Admin | |
Karolinska Institutet | College/University | Doctorate Degree | |
COMBIGENE AB | Pharmaceuticals: Major | Director/Board Member | |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
eTheRNA immunotherapies NV
![]() eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member | |
ModernaTX, Inc.
![]() ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Biotechnology | Chief Tech/Sci/R&D Officer |
Statistiques
Internationale
Royaume-Uni | 25 |
Etats-Unis | 14 |
Suède | 7 |
Australie | 5 |
Belgique | 3 |
Sectorielle
Health Technology | 23 |
Consumer Services | 12 |
Commercial Services | 4 |
Technology Services | 3 |
Finance | 3 |
Opérationnelle
Director/Board Member | 58 |
Chairman | 21 |
Corporate Officer/Principal | 13 |
Independent Dir/Board Member | 11 |
Chief Executive Officer | 8 |
Relations les plus connectées
- Bourse
- Insiders
- Matthew Wood
- Connexions Sociétés